Plenary Session 9
3月27日［土］17:00-18:30
|
| |
| |
Diabetes and Cardiorenal syndrome
|
|
|
| |
| |
|
|
| |
2型糖尿病患者は世界的にも、日本でも増大している。日本では700万人を上回る人が2型糖尿病と診断され、2030年までに約900万人に達すると予測されている。2型糖尿病は大血管・細小血管合併症を伴う慢性の進行性疾患であり、患者の生活の質（quality of life：QoL）に悪影響を及ぼし、さらに心血管死のリスクを高める。2型糖尿病が心血管系に及ぼす悪影響の機序としては、直接的な血管内皮機能障害に基づく動脈硬化性疾患の増強、毛細血管障害に伴う腎症、神経症、網膜症などがまず挙げられる。さらに近年では、心筋細胞への悪影響も指摘されており、これには心筋内代謝異常、ミトコンドリア機能異常、これらの結果としてのエネルギー産生異常が指摘されている。また心臓や腎臓の間質の線維化も挙げられる。また糖尿病に伴う腎症は近年DKD と言われ、腎機能の低下は体液貯留、貧血、交感神経の活性化、RAS系の活性化などを介して心臓に悪影響を与える。このセッションでは、「糖尿病と心腎連関を考える」と題し、2型糖尿病と心・腎疾患の連関について様々な角度からdiscussion を行いたい。この分野に関連する演題を募集したい。
The global prevalence of type 2 diabetes (T2DM) keeps rising and is estimated about 463 million in 2019. In Japan, the prevalence of T2DM is expected to increase from 7.4 million to approximately 8.9? million by 2030. T2DM is a chronic, progressive disease associated with a number of not only metabolic abnormalities but also macro- and microvascular comorbidities, which reduce patients’ quality of life (QoL) and cause cardiovascular death. Cardiovascular disease (CVD) is the leading cause of morbidity and mortality in patients with T2DM. The mechanisms of diabetes-associated cardiorenal injury may be multifactorial. One of the leading mechanisms is direct endothelial injury by high blood glucose level, that can cause atherosclerotic disease progression and microvascular disorders such as retinopathy, renal disease (DKD) and neuropathy. More recently, T2DM is considered to affect cardiomyocyte function. T2DM can cause mitochondrial injury, metabolic disturbance and energy production inside cardiomyocytes that cause heart failure. T2DM also causes interstitial fibrosis in both cardiac and renal tissues. DKD-mediated volume retention, anemia and sympathetic activation further worsen heart failure status. In this session, we would like to discuss in depth all the concern regarding T2DM and cardiorenal syndrome, and is open for many abstract submissions.
|
|
|
| |
| |
|
|
| |
| |
 |
|
Toyoaki Murohara
Department of Cardiology, Nagoya University Graduate School of Medicine, Nagoya
|
|
 |
|
John J. V. McMurray
BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
|
|
|
| |
| |
| |
| |
|
|
| |
| |
|
|
John J. V. McMurray
BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, UK
|
|
 |
|
Atsushi Kuno
Department of Cardiovascular, Renal and Metabolic Medicine, Sapporo Medical University, Sapporo
|
|
|
| |
| |
 |
|
Eri Kato
Department of Cardiology, Kyoto University School of Medicine, Kyoto
|
|
 |
|
Kenichi Matsushita
Division of Advanced Cardiovascular Therapeutics, Department of Cardiovascular Medicine, Kumamoto University Hospital, Kumamoto
|
|
|
| |
| |
 |
|
Hiroshi Iwata
Department of Cardiovascular Biology and Medicine, Juntendo University Graduate School of Medicine, Tokyo
|
|
|
|
|
|
|
| |
| |
|
|